Homology Medicines Inc reports results for the quarter ended in December - Earnings Summary

Q32 Bio

23/03/2022 22:19

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in December.
The mean expectation of ten analysts for the quarter was for a
loss of 59 cents per share.
    * Revenue fell 18.2% to $802.00 thousand from a year ago; 
analysts expected $741.89 thousand. 
    * Homology Medicines Inc's reported EPS for the quarter was
a loss
of 59 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.3%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Homology Medicines Inc shares had fallen by 4.4% this
quarter.
    * The company reported a quarterly loss of $33.58 million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 23 at 10:18 p.m.  ​All
figures in US dollars unless otherwise stated